Lung cancer's enduring global significance necessitates ongoing advancements in
diagnostics and therapeutics. Recent spotlight on proteomic and genetic biomarker research …

Simple Summary Biomarkers for the prediction and efficacy of therapies are an urgent
necessity for lung cancer patients. In this article, we summarize genomic and proteomic …

Until recently, the majority of genomic cancer research has been in discovery and validation;
however, as our knowledge of tumor molecular profiling improves, the idea of genomic …

Lung cancer is the cause of nearly 170,000 cancer deaths in the United States each year,
accounting for nearly 25% of all deaths from cancer. The 5-yr survival rate for lung cancer …

In lung cancer, genomics-driven comprehensive molecular profiling has identified novel
chemically and immunologically addressable vulnerabilities, resulting in an increasing …

During the last decade, high-throughput technologies including genomic, epigenomic,
transcriptomic and proteomic have been applied to further our understanding of the …

Simple Summary In the field of non-small cell lung cancer (NSCLC), there have been
significant advancements in genomic data and bioinformatics tools, which have improved …

Lung cancer is the leading cause of cancer-related death worldwide with a 5-year survival
rate of less than 15%, despite significant advances in both diagnostic and therapeutic …

Despite advances in the management of non-small-cell lung cancer (NSCLC), including the
introduction of targeted therapies such as epidermal growth factor receptor tyrosine kinase …

To explore the biology of lung adenocarcinoma (LUAD) and identify new therapeutic
opportunities, we performed comprehensive proteogenomic characterization of 110 tumors …